BioSpace News Archive

Perception Neuroscience, an atai Life Sciences company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd., announce a collaboration and licensing agreement for the development and commercialization of Perception’s lead molecule, PCN-101 in Japan as a potential treatment for mood disorders such as major depressive disorder and treatment-resistant depression.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that John Bencich, Achieve’s Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M-Vest and Maxim Group.

New Data Published in Scientific Reports Reveals Possible Biological Underpinnings of Cancer Patients Hyper-Immune Response to COVID-19 Infection

Aptose Biosciences Inc. announced the appointment of two key members to its management team to support the company’s expanding clinical CMC and regulatory functions: George P. Melko, Pharm.D., joins Aptose as Vice President, Regulatory Affairs; and Robert B. Killion Jr., Ph.D. has been named Vice President, CMC.

TearClear continues to make progress on the development of its first-in-class platform of preservative-free topical medications.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces a second clinical trial collaboration and supply agreement with subsidiaries of Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada).

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported fourth quarter and full year financial results for the period ending December 31, 2020.

– Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set to Initiate Early in the Second Quarter – – Clinical Data Readouts Expected in 2H21 for Lead PRMT5 Inhibitors PRT543 and PRT811 –

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the successful completion of a Phase 1 trial of PLN-1474, an oral, small-molecule selective inhibitor of the integrin α v β 1 in development for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis.

Oncology Pharma, Inc. (OTC: ONPH) revealed today the Company’s plans for growth and development of its intellectual property and business model. Key focal points include expansion of its cancer therapeutics through acquisition of license agreements and formation of synergistic partnerships and expansion of other niche therapeutics.